SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported a loss of $42 million in its third quarter.
The San Diego-based company said it had a loss of 29 cents per share.
The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 41 cents per share.
The drugmaker posted revenue of $94.6 million in the period, which also topped Street forecasts. Six analysts surveyed by Zacks expected $88.6 million.
Acadia shares have more than doubled since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $43.05, more than doubling in the last 12 months.